ArticleJAMA network open2025
Health Economic Analysis of an All-Virtual, At-Home Acute Care Model.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Errors in Commentary.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: An all-virtual, at-home acute care model, called Safer@Home, was found to enable an average 4-day reduction in hospital length of stay. The program is not currently reimbursed. Objective: To estimate costs and savings associated with the Safer@Home program from a hospital and payer perspective. Design, Setting, and Participants: This retrospective, economic evaluation analyzed costs associated with the Safer@Home program at a large, academic, public, level I trauma hospital near downtown Los Angeles, California, between September 2022 and August 2023. Patients with 1 of 10 protocolized diagnoses were eligible for the program. Data analysis occurred from January to July 2024. Exposure: Patients who presented to the hospital and were enrolled in an all-virtual, at-home acute care program called Safer@Home were compared with matched controls with similar diagnoses who received entirely in-hospital care. Main Outcome and Measures: The primary outcome was estimated net hospital and payer cost with the program vs without. Revenue from third-party payers was compared with hospital variable costs. Results: A total of 876 patients receiving care in the Safer@Home program (541 male [61.8%]; mean [SD] age, 54 [15 years]; mean [SD] expected mortality, 1.6% [4.7%]; mean [SD] case mix index, 1.27 [0.66]) were compared with 1590 matched control patients (901 male [56.7%]; mean [SD] age, 52 [20] years; mean [SD] expected mortality, 1.9% [5.9%]; mean [SD] case mix index, 1.26 [0.59]). Safer@Home enabled net hospital savings of $5.60 million, calculated as variable costs saved minus revenue lost, for the enrolled patients. Overall savings were due to net savings for Medicaid ($8380 per patient) and unfunded patients ($10 934 per patient), but net losses were due to significant loss of revenue for Medicare (-$4143 per patient) and commercially insured patients (-$25 999 per patien). Modeling demonstrated that revenue based on payer mix, rather than avoided variable hospital costs, was the primary factor of net hospital savings and losses. Absent reimbursement, the program was cost-saving to payers in all modeled scenarios. Creating reimbursement rates of 50% to 60% of hospital costs would enable the program to be cost-saving to both the hospital and payers, across payer mixes. Conclusions and Relevance: In this economic evaluation study, an all-virtual, at-home acute care program was associated with both hospital and payer savings; however, in the absence of reimbursement, it was only cost-saving to hospitals for Medicaid-funded or uninsured patients. These findings suggest that payer reform is needed to enable program generalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.